Apex Trader Funding - News
Bioretec Ltd's half-year report January-June 2024: RemeOs™ trauma screw controlled launch in the U.S. yielded expected positive clinical results
Bioretec Ltd Company announcement 15 August 2024 at 8:00 a.m.
TAMPERE, Finland, Aug. 15, 2024 /PRNewswire/ -- This announcement is a summary of Bioretec Ltd's half-year report January-June 2024. The complete half-year report with tables is attached to this release as a pdf file and available at the company's web pages at https://bioretec.com/investors/investors-in-english/releases.
April-June 2024 in brief
Net sales increased by 68% and amounted to EUR 1,379 thousand (4-6/2023: EUR 820 thousand).
Sales margin (excl. other income) was EUR 1,033 (609) thousand, or 74.9% (74.3%) of net sales.
Profit (loss) for the reporting period was EUR -787 (-1,518) thousand. The comparison period included the cost of financing arrangement amounting to EUR 795 thousand.
January-June 2024 in brief
Net sales amounted to EUR 2,061 thousand (1-6/2023: EUR 1,891 thousand).
Sales margin (excl. other income) was EUR 1,451 (1,327) thousand or 70.4% (70.2%) of net sales. The sales margin in January-June 2024 includes other income of EUR 72 (0) thousand accrued relating to a Business Finland grant.
Profit (loss) for the reporting period was EUR -1,884 (-2,075) thousand.
Earnings per share (undiluted) were EUR -0.09 (-0.11).
Key figures
EUR 1,000
4-6/2024
4-6/2023
Change, %
1-6/2024
1-6/2023
Change, %
1-12/2023
Net sales
1,379
820
68.3 %
2,061
1,891
9.0 %
3,906
Sales margin
1,045
609
71.6 %
1,523
1,327
14.8 %
2,810
Sales margin (excl. other income)
1,033
609
69.8 %
1,451
1,327
9.4 %
2,728
Sales margin, % of net sales
75.7
74.3
73.9 %
70.2 %
71.9 %
Sales margin% (excl. other income)
74.9
74.3
70.4 %
70.2 %
69.8 %
EBITDA
-752
-639
17.8 %
-1,864
-1,130
65.0 %
-2,833
EBIT
-782
-690
13.4 %
-1,921
-1,233
55.8 %